Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 294963, 7 pages
http://dx.doi.org/10.1155/2014/294963
Research Article

Added Value of QuantiFERON TB-Gold in-Tube for Detecting Latent Tuberculosis Infection among Persons Living with HIV/AIDS

1University of Brasilia (UnB), Campus Universitário Darcy Ribeiro, 70910-900 Brasília, DF, Brazil
2SHA, Conjunto 5 chácara 47, Quadra D, Arniqueiras, 71995-297 Taguatinga, DF, Brazil
3Catholic University of Brasilia (UCB), Campus I, QS 07 Lote 01 EPCT, Águas Claras, 71966-700 Taguatinga, DF, Brazil
4Federal University of Rio de Janeiro (UFRJ), Avenida Brigadeiro Trompowsky s/n°, Ilha do Fundão Prédio do Hospital Universitário Clementino Fraga Filho, 11° andar Bloco F, Sala 4, 21941-590 Rio de Janeiro, RJ, Brazil
5Montreal Chest Institute, McGill University, 3650 St. Urbain Street, Montreal, QC, Canada H2X 2P4

Received 30 January 2014; Accepted 13 May 2014; Published 29 May 2014

Academic Editor: Christen Rune Stensvold

Copyright © 2014 Josiane Maria Oliveira Souza et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. World Health Organization, Guidelines for Intensified Tuberculosis Case-Finding and Isoniazid Preventive Therapy for People Living with HIV in Resource-Constrained Settings, World Health Organization, Geneva, Switzerland, 2011.
  2. World Health Organization, Global Tuberculosis Report 2013, World Health Organization, Geneva, Switzerland, 2013.
  3. K. L. Dierberg and R. E. Chaisson, “Human immunodeficiency virus-associated tuberculosis. Update on prevention and treatment,” Clinics in Chest Medicine, vol. 34, no. 2, pp. 217–228, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. T. Samandari, T. B. Agizew, S. Nyirenda et al., “6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial,” The Lancet, vol. 377, no. 9777, pp. 1588–1598, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. S. D. Lawn, R. Wood, K. M. de Cock, K. Kranzer, J. J. Lewis, and G. J. Churchyard, “Antiretrovirals and isoniazid preventive therapy in the prevention of HIV-associated tuberculosis in settings with limited health-care resources,” The Lancet Infectious Diseases, vol. 10, no. 7, pp. 489–498, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. National Institute for Health and Clinical Excellence, Tuberculosis: Clinical Diagnosis and Management of Tuberculosis, and Measures for Its Prevention and Control, National Institute for Health and Clinical Excellence, London, UK, 2011.
  7. World Health Organization, WHO Policy on Collaborative TB/HIV Activities: Guidelines for National Programmes and Other Stakeholder, World Health Organization, Geneva, Switzerland, 2012.
  8. J. E. Kaplan, C. Benson, K. H. Holmes, J. T. Brooks, A. Pau, and H. Masur, “Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the national institutes of health, and the HIV medicine association of the infectious diseases society of America,” Morbidity and Mortality Weekly Report: Recommendations and Reports, vol. 58, no. 4, pp. 1–207, 2009. View at Google Scholar · View at Scopus
  9. Ministério da Saúde (Brasil), Secretaria de Vigilância em Saúde, Departamento de DST, Aids e Hepatites Virais, Protocolo Clínico e Diretrizes Terapêuticas para Adultos vivendo com HIV/Aids: versão preliminar, Ministério da Saúde, Brasília, Brazil, 2013.
  10. D. Menzies, “Interpretation of repeated tuberculin tests: boosting, conversion, and reversion,” The American Journal of Respiratory and Critical Care Medicine, vol. 159, no. 1, pp. 15–21, 1999. View at Google Scholar · View at Scopus
  11. A. Trajman, R. E. Steffen, and D. Menzies, “Interferon-gamma release assays versus tuberculin skin testing for the diagnosis of latent tuberculosis infection: an overview of the evidence,” Pulmonary Medicine, vol. 2013, Article ID 601737, 11 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Santin, L. Muñoz, and D. Rigau, “Interferon-γ release assays for the diagnosis of tuberculosis and tuberculosis infection in HIV-infected adults: a systematic review and meta-analysis,” PLoS ONE, vol. 7, no. 3, Article ID e32482, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Cattamanchi, R. Smith, K. R. Steingart et al., “Interferon-gamma release assays for the diagnosis of latent tuberculosis infection in HIV-infected individuals: a systematic review and meta-analysis,” Journal of Acquired Immune Deficiency Syndromes, vol. 56, no. 3, pp. 230–238, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. C. M. Denkinger, K. Dheda, and M. Pai, “Guidelines on interferon-γ release assays for tuberculosis infection: concordance, discordance or confusion?” Clinical Microbiology and Infection, vol. 17, no. 6, pp. 806–814, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. Canada Communicable Disease Report, “Recommendations on interferon gamma release assays for the diagnosis of latent tuberculosis infection—2010 update,” Canada Communicable Disease, An Advisory Committee Statement (ACS) and Canadian Tuberculosis Committee (CTC), vol. 36, no. 5, 2010. View at Google Scholar
  16. Centers for Disease Control and Prevention, “Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection—United States, 2010,” Morbidity and Mortality Weekly Report: Recommendations and Reports, vol. 59, no. 5, pp. 1–25, 2010. View at Google Scholar
  17. C. G. M. Erkens, M. Kamphorst, I. Abubakar et al., “Tuberculosis contact investigation in low prevalence countries: a European consensus,” European Respiratory Journal, vol. 36, no. 4, pp. 925–949, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. R. E. Steffen, R. Caetano, M. Pinto et al., “Cost-effectiveness of quantiferon-TB gold-in-tube versus tuberculin skin testing for contact screening and treatment of latent tuberculosis infection in Brazil,” PLoS ONE, vol. 8, no. 4, Article ID e59546, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. Ministério da Saúde (Brasil), Secretaria de Vigilância em Saúde, Programa Nacional de DST e Aids, Critérios de definição de casos de aids em adultos e crianças, Ministério da Saúde, Brasília, Brazil, 2003.
  20. Cellestis, QuantiFERON-TB Gold: Método in tubo, Teste de interferon-gama para sangue total, para medição de respostas aos péptidos antigénicos ESAT-6, CFP-10 & TB7. 7, Folleto informativo para diagnóstico in vitro, Cellestis Limited, Australia e Cellestis GmbH, Hannover, Germany, 2009.
  21. Ministério da Saúde (Brasil), Secretaria de Vigilância em Saúde, Programa Nacional de Controle da Tuberculose, Manual de Recomendações para o Controle da Tuberculose no Brasil, Ministério da Saúde, Brasília, Brazil, 2011.
  22. A. F. Luetkemeyer, E. D. Charlebois, L. L. Flores et al., “Comparison of an interferon-γ release assay with tuberculin skin testing in HIV-infected individuals,” The American Journal of Respiratory and Critical Care Medicine, vol. 175, no. 7, pp. 737–742, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Santin, S. Casas, M. Saumoy et al., “Detection of latent tuberculosis by the tuberculin skin test and a whole-blood interferon-γ release assay, and the development of active tuberculosis in HIV-seropositive persons,” Diagnostic Microbiology and Infectious Disease, vol. 69, no. 1, pp. 59–65, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. N. J. Talati, U. Seybold, B. Humphrey et al., “Poor concordance between interferon-γ release assays and tuberculin skin tests in diagnosis of latent tuberculosis infection among HIV-infected individuals,” BMC Infectious Diseases, vol. 9, article 15, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. C. Stephan, T. Wolf, U. Goetsch et al., “Comparing QuantiFERON-tuberculosis gold, T-SPOT tuberculosis and tuberculin skin test in HIV-infected individuals from a low prevalence tuberculosis country,” AIDS, vol. 22, no. 18, pp. 2471–2479, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. E. G. Teixeira, D. Menzies, G. W. Comstock et al., “Latent tuberculosis infection among undergraduate medical students in Rio de Janeiro State, Brazil,” International Journal of Tuberculosis and Lung Disease, vol. 9, no. 8, pp. 841–847, 2005. View at Google Scholar · View at Scopus
  27. K. Z. Siqueira and S. A. Mendonça, “Indicação da prova tuberculínica e infecção latente da tuberculose em HIV-positivos, Município de Blumenau, Estado de Santa Catarina, Brasil, 2004–2009,” Epidemiologia e Serviços de Saúde, vol. 21, no. 4, pp. 635–644, 2012. View at Google Scholar
  28. J. M. Ramos, C. Robledano, M. Masiá et al., “Contribution of Interferon gamma release assays testing to the diagnosis of latent tuberculosis infection in HIV-infected patients: a comparison of QuantiFERON-TB gold in tube, T-SPOT.TB and tuberculin skin test,” BMC Infectious Diseases, vol. 12, article 169, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. P. Narasimhan, J. Wood, C. R. MacIntyre, and D. Mathai, “Risk factors for tuberculosis,” Pulmonary Medicine, vol. 2013, Article ID 828939, 11 pages, 2013. View at Publisher · View at Google Scholar
  30. S. A. Clark, S. L. Martin, A. Pozniak et al., “Tuberculosis antigen-specific immune responses can be detected using enzyme-linked immunospot technology in human immunodeficiency virus (HIV)-1 patients with advanced disease,” Clinical and Experimental Immunology, vol. 150, no. 2, pp. 238–244, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. M. C. Aichelburg, A. Rieger, F. Breitenecker et al., “Detection and prediction of active tuberculosis disease by a whole-blood interferon-γ release assay in HIV-l-infected individuals,” Clinical Infectious Diseases, vol. 48, no. 7, pp. 954–962, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. C. Akolo, I. Adetifa, S. Shepperd, and J. Volmink, “Treatment of latent tuberculosis infection in HIV infected persons,” Cochrane Database of Systematic Reviews, no. 1, Article ID CD000171, 2010. View at Google Scholar · View at Scopus
  33. World Health Organization, Use of Tuberculosis Interferon-Gamma Release Assays (IGRAs) in Low- and Middle-Income Countries: Policy Statement, World Health Organization, Geneva, Switzerland, 2011.
  34. Ministério da Saúde (Brasil), Secretaria de Vigilância em Saúde, Departamento de DST, Aids e Hepatites Virais, Boletim Epidemiológico—Aids e DST, Ano II—no. 1, até semana epidemiológica 26a, Ministério da Saúde, 2013.